Cargando…

Dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration‐resistant prostate cancer

INTRODUCTION: Prostate cancer with a microsatellite instability‐high or mismatch repair‐deficient status is not common. Few reports of the response to pembrolizumab in metastatic castration‐resistant prostate cancer in a real‐world setting have been reported. This case report describes a dramatic re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kageyama, Takumi, Soga, Norihito, Sekito, Sho, Kato, Seiichi, Ogura, Yuji, Kojima, Takahiro, Kanai, Masahiro, Inoue, Takahiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626308/ https://www.ncbi.nlm.nih.gov/pubmed/36341181 http://dx.doi.org/10.1002/iju5.12508

Ejemplares similares

Roles of the PARP Inhibitor in BRCA1 and BRCA2 Pathogenic Mutated Metastatic Prostate Cancer: Direct Functions and Modification of the Tumor Microenvironment
por: Inoue, Takahiro, et al.
Publicado: (2023)

Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer
por: Han, Harry J., et al.
Publicado: (2020)

Multiple Brain Pseudoprogression in a Patient With NSCLC Treated With Pembrolizumab
por: Moliner, Laura, et al.
Publicado: (2020)

Pseudoprogression during treatment with pembrolizumab followed by rechallenge with chemotherapy in metastatic colorectal cancer: A case report
por: Trabjerg, Natacha Dencker, et al.
Publicado: (2019)

Dramatic response of refractory metastatic squamous cell carcinoma of the skin with cetuximab/pembrolizumab
por: Hober, Candice, et al.
Publicado: (2021)

Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer
por: Tucker, Matthew D., et al.
Publicado: (2019)

Distinct clinical and magnetic resonance features of metastatic hepatocellular carcinoma treated with pembrolizumab: A case report of late response after pseudoprogression
por: Grierson, Patrick, et al.
Publicado: (2017)

Pembrolizumab for a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high
por: Fujiwara, Motohiro, et al.
Publicado: (2020)

Multiple oligodendroglioma with pseudoprogression
por: Matsuyama, Junko
Publicado: (2012)

Pseudoprogression of brain tumors
por: Thust, Stefanie C., et al.
Publicado: (2018)

Pseudoprogression and Immunotherapy Phenomena
por: Waxman, Elizabeth S., et al.
Publicado: (2020)

Pseudoprogression After Palbociclib with Aromatase Inhibitors Treatment in Metastatic Breast Cancer
por: Huang, Weiwei, et al.
Publicado: (2020)

A case of pseudoprogression in avelumab maintenance therapy for metastatic bladder cancer
por: Hayakawa, Nozomi, et al.
Publicado: (2022)

Dramatic Response to First Line Single Agent Pembrolizumab in Anaplastic Thyroid Carcinoma
por: Spalart, Valérie, et al.
Publicado: (2019)

Successfully Treated Lung and Renal Metastases from Primary Chondrosarcoma of the Scapula with Radiofrequency Ablation and Surgical Resection
por: Sekito, Sho, et al.
Publicado: (2019)

Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report
por: Ozaki, Yukinori, et al.
Publicado: (2017)

Case report: Postoperative abdominal recurrence of pulmonary pleomorphic carcinoma showed a dramatic response to S-1 after pembrolizumab
por: Kojima, Yuichi, et al.
Publicado: (2021)

Variant allele frequency changes in TP53 predict pembrolizumab response in patients with metastatic urothelial carcinoma
por: Hamada, Kazuki, et al.
Publicado: (2023)

Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
por: Sugimoto, Mikio, et al.
Publicado: (2022)

Pseudoprogression in low-grade glioma
por: Slater, Jason M., et al.
Publicado: (2019)

Dramatic response to pembrolizumab with chemotherapy followed by salvage surgery in a lung cancer patient
por: Saito, Shunichi, et al.
Publicado: (2021)

Metastatic Castration-Resistant Prostate Cancer: Two Case Reports of Dramatic Response with Abiraterone Acetate in Patients Heavily Pretreated with Chemotherapy
por: Dupuy, Laura, et al.
Publicado: (2011)

Determination and clinical significance of bone pseudoprogression in hormone receptor-positive metastatic breast cancer
por: Lin, Mingxi, et al.
Publicado: (2021)

Pathological pseudoprogression to anti-PD-1 inhibitor in metastatic periampullary carcinoma: Case report
por: Wang, Junhui, et al.
Publicado: (2023)

Immune-Therapy-Related Toxicity Events and Dramatic Remission After a Single Dose of Pembrolizumab Treatment in Metastatic Thymoma: A Case Report
por: Shen, Li, et al.
Publicado: (2021)

Role of Signaling Transduction Pathways in Development of Castration-Resistant Prostate Cancer
por: Inoue, Takahiro, et al.
Publicado: (2011)

Pseudoprogression as an adverse event of glioblastoma therapy
por: Balaña, Carmen, et al.
Publicado: (2017)

Pseudoprogression with Neoadjuvant Immunotherapy for Cutaneous Melanoma
por: Garcia, Diogo, et al.
Publicado: (2021)

Surgical Castration in Hormone-Refractory Metastatic Prostate Cancer Patients Can Be an Alternative for Medical Castration
por: Zaitsu, Masayoshi, et al.
Publicado: (2012)

A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
por: Watanabe, Yukinobu, et al.
Publicado: (2021)

First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590
por: Kojima, Takashi, et al.
Publicado: (2022)

Clinical Efficacy and Openness to New Challenges of Low Dose Rate Brachytherapy for Prostate Cancer
por: Kato, Manabu, et al.
Publicado: (2023)

Pembrolizumab dramatically resolves choroidal metastatis from esophageal adenocarcinoma and restores vision: a case report
por: Barrett, Dianne, et al.
Publicado: (2021)

A case report of neuromyelitis optica spectrum disorder induced by pembrolizumab treatment for lung adenocarcinoma: a clinical and immunohistochemical study
por: Hirano, Shigeki, et al.
Publicado: (2022)

A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
por: Graff, Julie N, et al.
Publicado: (2020)

Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)
por: McNeel, Douglas G, et al.
Publicado: (2022)

Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report
por: Yoshida, Tsukasa, et al.
Publicado: (2022)

Delayed pseudoprogression of a vestibular schwannoma postradiosurgery
por: Malone, Janna, et al.
Publicado: (2020)

Pseudoprogression in lung cancer: a case report
por: Meoni, Giulia, et al.
Publicado: (2020)

Retrospective examination of pseudoprogression in IDH mutant gliomas
por: Wetzel, Ethan A, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7t6o1ovfni83ossl7pv9bit3gf